Gamida Cell and Editas Medicine have entered a partnership to explore the potential of using gene-editing technology to enhance the…
Articles by Alice Melão
The development and commercialization of TNB-383B — an anti-BCMA antibody for the potential treatment of multiple myeloma — is being advanced…
A maintenance treatment with thalidomide at 100 mg a day was safe and seen to delay disease progression by more than…
Results from the first in-human clinical trial assessing Amgen’s immunotherapy AMG 420 showed promising results in multiple myeloma patients…
Seattle Genetics is recruiting patients with relapsed or refractory multiple myeloma into a Phase 1 clinical trial to study…
Treatment with Darzalex (daratumumab) plus standard Revlimid (lenalidomide) and dexamethasone significantly delays the time to disease progression or…
The U.S. Food and Drug Administration (FDA) has granted priority review to Karyopharm Therapeutics’ application requesting accelerated approval of its…
Among those with blood cancers — including myeloma, lymphoma, and leukemia — only 59% fully understand their diagnosis, data from…
The U.S. Food and Drug Administration (FDA) has approved Adaptive Biotechnologies’ clonoSEQ Assay to detect and monitor minimal…
SELLAS Life Sciences’ lead therapy candidate galinpepimut-S (GPS) received orphan medicinal product designation from the European Medicines Agency for…